Decline in forced vital capacity (FVC) in subjects with systemic sclerosis-associated interstitial lung disease (SSc-ILD) in the SENSCIS trial versus hypothetical reference subjects without lung disease

Maher TM et al.
 

Acceder

Decline in forced vital capacity (FVC) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) with and without dyspnoea: data from the SENSCIS trial

Volkmann ER et al.

 

Acceder

Risk of malnutrition in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD): further analyses of the SENSCIS trial

Volkmann ER et al.


 

Acceder

Efficacy of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) and internal organ involvement: data from the SENSCIS trial

Allanore Y et al.
 

Acceder

Post-trial survey of participants of a Phase 3 clinical trial in SSc-ILD

Galetti I et al.



 

Acceder

Patient preferences for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD): a discrete choice experiment

Bruni C et al.

 

Acceder